{"ok":true,"nota":{"id":"fa664f1787558ad8","slug":"logran-que-celulas-inmunes-destruyan-melanomas-en-ratones-sin-quimiote-fa664f","titulo":"Logran que células inmunes destruyan melanomas en ratones sin quimioterapia previa","resumen":"Diseñaron un receptor que hace que los linfocitos se multipliquen con un factor de crecimiento usado en oncología, en lugar de la IL-2. En ratones con melanoma, las células eliminaron el tumor sin necesidad de agotar el sistema inmune antes.","fuente":"biorxiv","fuenteNombre":"bioRxiv · preprints","color":"#be2628","autor":"Preshaw, S. C., Fuller, M. E., Powell, C. J., Milne, K., Sewell, K., Adamson, M. B., Pearson-Lund, A., Joly, M., Goodwin","url":"https://www.biorxiv.org/content/10.64898/2026.10.22.760485v1?rss=1","imagen":"/hoy/portada/fa664f1787558ad8","tema":"salud","subtemas":["melanoma","inmunoterapia","linfocitos t","terapia celular","investigación en ratones"],"entidades":["bioRxiv"],"formato":"dato","entretenimiento":false,"pubTs":"2026-10-24T00:00:00.000Z","indexTs":"2026-10-24T15:21:10.758Z","hash":"b77e555290c6fe6386630e91db01483b004aa483d91eff1faee8bc74317d876e","tsa":{"time":"Oct 24 15:21:44 2026 GMT","provider":"freetsa.org","sobre":"sello"},"stats":{"views":0,"likes":0,"clicks":0,"dwell":0},"tipo":"normal","registro":"hallazgo","porQueImporta":"Hoy estas terapias con células del propio paciente exigen quimioterapia fuerte previa y dosis altas de IL-2, que traen efectos secundarios serios. Este diseño usa el G-CSF, un fármaco que ya se aplica a pacientes oncológicos para reponer glóbulos blancos, y eso podría bajar la toxicidad del tratamiento. Todavía son experimentos en ratones, así que pasará un buen tiempo antes de que alguien de acá pueda beneficiarse.","quienFirma":"bioRxiv · preprints","confianza":"preprint","consulta":null},"sello":{"hash":"b77e555290c6fe6386630e91db01483b004aa483d91eff1faee8bc74317d876e","sello":"3d272aa70477e17ea0b9b9473133765623e77a6b8c02acd1ffb72590175cf440","beacon":{"drand":{"cadena":"8990e7a9aaed2ffed73dbd7092123d6f289930540d7651336225dc172e51b2ce","ronda":6580809,"aleatorio":"3d35063162a4e7d3668b9babf034358bcf06064f5d74d59d17a1cdb95fa80b6d","tiempo":"2026-10-24T15:21:30.000Z"},"nist":{"cadena":2,"pulso":1997598,"salida":"EB07E7F252E8AF18A2554C318A0C5EC75263B6A954197ACB0321A623F27C616EB83954B3A5FCDAD3DE3C057E7D630FAE38061F776F8741FAF3AA8AF72651D6F0","tiempo":"2026-10-24T15:21:00.000Z"},"noAntes":"2026-10-24T15:21:30.000Z"},"verificacion":{"drand":true,"nist":true},"tsa":{"time":"Oct 24 15:21:44 2026 GMT","provider":"freetsa.org","sobre":"sello"},"original":{"titulo":"Engineered T cells controlled by granulocyte colony-stimulating factor eradicate murine melanoma without lymphodepletion or interleukin-2","descripcion":"Tumour-infiltrating lymphocyte (TIL) therapy can be effective against metastatic melanoma, including immune checkpoint-resistant disease, but current protocols require lymphodepletion and high-dose interleukin-2 (IL-2), which can cause substantial toxicity. To overcome this limitation, we engineered a chimeric receptor, G2R, that generates an IL-2-like proliferative signal in response to granulocyte colony-stimulating factor (G-CSF), a well-tolerated cytokine widely used in oncology. Human T cells expressing G2R expanded in vitro in response to G-CSF in place of IL-2 or interleukin-15 (IL-15), and the three cytokines induced broadly similar intracellular signalling and cytokine secretion pro","pubDate":"2026-10-24","url":"https://www.biorxiv.org/content/10.64898/2026.10.22.760485v1?rss=1"},"indexado":"2026-10-24T15:21:10.758Z"}}